[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP0025232B1 - 4-(Substituierte Thiazolyl)-3-hydroxy-3-pyrrolin-2,5-dion-Verbindungen, Verfahren zur Herstellung und sie enthaltende pharmazeutische Zusammensetzung - Google Patents

4-(Substituierte Thiazolyl)-3-hydroxy-3-pyrrolin-2,5-dion-Verbindungen, Verfahren zur Herstellung und sie enthaltende pharmazeutische Zusammensetzung Download PDF

Info

Publication number
EP0025232B1
EP0025232B1 EP80105409A EP80105409A EP0025232B1 EP 0025232 B1 EP0025232 B1 EP 0025232B1 EP 80105409 A EP80105409 A EP 80105409A EP 80105409 A EP80105409 A EP 80105409A EP 0025232 B1 EP0025232 B1 EP 0025232B1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutically acceptable
compounds
compound
acceptable salts
pyrroline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP80105409A
Other languages
English (en)
French (fr)
Other versions
EP0025232A1 (de
Inventor
Edward J. Cragoe Jr.
Clarence S. Rooney
Haydn W.R. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to AT80105409T priority Critical patent/ATE2271T1/de
Publication of EP0025232A1 publication Critical patent/EP0025232A1/de
Application granted granted Critical
Publication of EP0025232B1 publication Critical patent/EP0025232B1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • glycolate oxidase The immediate metabolic precursor of the majority of the oxalate in the urine of a typical patient is glyoxylic acid. In turn its most important precursor is glycolic acid.
  • glycolate oxidase is able to carry out the oxidation of glycolic acid, through glyoxylic acid, to oxalic acid. Inhibition of this enzyme will, therefore, reduce the concentration of oxalic acid in the kidney and bladder, reducing the probability that calcium oxalate crystallization will occur.
  • inhibitors of glycolate oxidase provide a specific approach to the prevention and treatment of calcium oxalate renal lithiasis.
  • Preferred compounds are those wherein
  • Still further preferred specific compounds are: and pharmaceutically acceptable salts thereof.
  • Glyoxylate is the major immediate forerunner of oxalate.
  • An inhibitor of glycolate oxidase (G.O.) will inhibit both the conversion of glyoxylate to oxalate as well as the production of glyoxylate from glycolate.
  • Compounds of formula (1) are potent inhibitors of glycolate oxidase and thus are useful in restricting oxalate levels in the blood and urine. Further, they are useful in the treatment and prevention of renal disease due to calcium oxalate stone formation in the kidney and bladder. They may be useful in the treatment of the genetically inherited diseases termed Hyperoxaluria types I and II in which very high levels of metabolic oxalic acid are present.
  • the compounds (III) are prepared generally by the method of Fairfull, Lowe and Peak, J. Chem. Soc., 742 (1952).
  • the nitrile (II) prepared by known methods, is reacted with an excess of hydrogen sulfide gas in the presence of excess triethylamine in a basic organic solvent such as pyridine.
  • a basic organic solvent such as pyridine.
  • the thiazole rings (IV) are assembled by the classic Hantzsch procedure using the thioamide (III) and ethyl 4-chloroacetoacetate or its homologs.
  • Preparation of the pyrrolinediones from the amides (V) is accomplished by reacting (V) with diethyl oxalate in DMF with strong base such as potassium t-butoxide or sodium ethoxide under an inert atmosphere.
  • strong base such as potassium t-butoxide or sodium ethoxide under an inert atmosphere.
  • the reaction can also be carried out in alcoholic solvents such as methanol, ethanol and isopropanol with the corresponding alkoxides as base.
  • dehydration to the nitrile is carried out by standard methods well known in the art (e.g., with p-toluenesulfonyl chloride in pyridine or thionyl chloride in DMF).
  • An alternative route to the nitrile intermediate involves reaction of the thioamide directly with the appropriate halomethylketone-substituted alkyl cyanide. Reaction of the nitrile with diethyl oxalate in the presence of base (usually sodium or potassium alkoxide in solvents such as methanol, ethanol, dimethylformamide, or toluene at room temperature to 60°C) provides the intermediate 3-cyano-2- keto acid ester.
  • base usually sodium or potassium alkoxide in solvents such as methanol, ethanol, dimethylformamide, or toluene at room temperature to 60°C
  • Cyclization to the hvdroxypyrrolinedione (I) is carried out by reaction first in strong acid, such as sulfuric or methanesulfonic acid for several hours to overnight, and then mixing the solution with ethanol containing 5-10% water. Evaporation of the ethanol and extraction with chloroform or ethyl acetate provides the desired 3-hydroxy-3-pyrroline-2,5-dione product.
  • the sulfuric or methanesulfonic acid solutions may be quenched with ice-water.
  • the nitrile intermediate may be first converted to the imino ether with cold HCI in ethanol.
  • the imino ether when heated in chloroform, is converted to the hydroxypyrrolinedione (I).
  • the bromomethyl ketone intermediate is reacted with the appropriate ethoxycarbonyl- alkylthioamide in refluxing ethanol to form the 4-substituted-2-thiazolylalkanoic acid ethyl ester which is converted to the amide and subsequently to the hydroxypyrrolinedione derivative by the procedures outlined above.
  • the compounds of formula are strong organic acids with a pKa in the range 2-4. These salts are readily formed with the usual inorganic cations such as sodium, potassium and ammonium. Salts with organic amines such as trimethylamine, triethylamine, n-butylamine and the like are also very stable.
  • the neutralization can be carried out by a variety of procedures known to the art to be generally useful for the preparation of such salts. The choice of the most suitable procedure will depend on a variety of factors including convenience of operation, economic considerations, and particularly the solubility characteristics of the particular free base, the acid, and the acid addition salt.
  • the compounds of formula (I) are utilized for the stated utilities by formulating them in a composition such as tablet, capsule or elixir for oral administration. Sterile solutions or suspensions can be used for parenteral administration. About 10 to 200 mg of the compound of formula (I) or a physiologically acceptable salt is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in the composition is such that dosage in the range indicated is obtained. The total daily dose will be in the 30 to 2000 mg range and preferably in the range of 50 mg. to 1000 mg.
  • Illustrative of the adjuvants which may be incorporated in tablets, capsules and the like are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; and excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, lactose, or saccharin; a flavouring agent such as peppermint, oil of wintergreen or cherry.
  • a liquid carrier such as a fatty oil.
  • tablets may be coated with shellac, sugar or the like.
  • a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavouring such as cherry or orange flavor.
  • Sterile compositions for injection can be formulated according to conventional pharmaceutical practice by dissolving or suspending the active substance in a conventional vehicle such as water for injection, a naturally occurring vegetable oil like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or a synthetic fatty vehicle like ethyl oleate or the like. Buffers, preservatives, antioxidants and the like can be incorporated as required.
  • the extract was washed with water (2 x 100 ml), dried (MgS0 4 ) and evaporated to a semi-solid which contained the desired ester and the corresponding acid.
  • the mixture was dissolved in ethanol (100 ml) saturated with hydrogen chloride and the solution was allowed to stand at room temperature for 1 day. The solution was evaporated to dryness and the ester was used without further purification for preparing the amide.
  • a mixture of the substituted acetamide (10 mmoie), diethyl oxalate (1.533 g, 10.5 mmole) and dry dimethylformamide (20 ml) is stirred under nitrogen or argon and cooled in an ice-bath.
  • Potassium t-butoxide (2.464 g, 22 mmole) is added in two equal portions 15 minutes apart and the reaction mixture is stirred for about 30 minutes in the ice-bath and then at room temperature overnight.
  • the reaction mixture is poured into ice-water (100 ml).
  • the aqueous mixture is extracted with ethyl acetate (2 x 35 ml) and then acidified with 6N hydrochloric acid in order to precipitate the product.
  • the product is either collected by filtration or by extraction with ethyl acetate.
  • the potassium salt is not soluble when the reaction mixture is quenched in ice-water, then it is necessary to acidify the resulting suspension and collect the product by filtration.
  • the crude product is generally less pure when obtained in this way.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (9)

1. Die Verbindungen mit der Struktur:
Figure imgb0052
worin
m 0 oder 1 ist;
R1, R2 und R3 unabhängig voneinander Wasserstoff, Halogen, Niedrigalkyl mit 1 bis 6 Kohlenstoffen, Trifluormethyl und Niedrigalkoxy mit 1 bis 6 Kohlenstoffen sind, oder pharmazeutisch annehmbare Salze davon, mit der Maßgabe, daß die Substituenten an dem Thiazolylring nicht benachbart sind.
2. Die Verbindungen nach Anspruch 1, worin m 0 ist, mit der Struktur:
Figure imgb0053
worin R4, R5 und R6 unabhängig voneinander Wasserstoff, Halogen, Niedrigalkyl mit 1 bis 6.Kohlenstoffatomen, Niedrigalkoxy mit 1 bis 6 Kohlenstoffatomen sind, und pharmazeutisch annehmbare Salze davon.
3. Die Verbindungen nach Anspruch 2, worin
R4 Wasserstoff oder Niedrigalkoxy mit 1 bis 3 Kohlenstoffatomen ist;
R5 und R6 Chlor sind, und pharmazeutisch annehmbare Salze davon.
4. Die Verbindungen nach Anspruch 2, worin R4 und R5 Wasserstoff sind und R6 Brom ist.
5. Die Verbindung nach Anspruch 2 mit der Struktur:
Figure imgb0054
Figure imgb0055
und pharmazeutisch annehmbare Salze davon.
6. Die Verbindung nach Anspruch 2 mit der Struktur:
Figure imgb0056
und pharmazeutisch annehmbare Salze davon.
7. Eine pharmazeutische Zusammensetzung, umfassend eine wirksame Menge einer Verbindung nach Anspruch 1 oder ein pharmazeutisch annehmbares Salz davon und einen pharmazeutisch annehmbaren Träger.
8. Ein Verfahren zur Herstellung von Verbindungen nach Anspruch 1, umfassend das Umsetzen einer Verbindung der Formel
Figure imgb0057
mit Diethyloxalat in einer starken Base und einem Lösungsmittel zur Gewinnung des gewünschten Produktes.
9. Ein Verfahren zur Herstellung einer Verbindung nach Anspruch 1, umfassend
(a) das Umsetzen einer Verbindung der Formel
Figure imgb0058
mit Diethyloxalat in Gegenwart einer starken Base und eines Lösungsmittels unter Bildung einer Verbinduna der Formel
Figure imgb0059
(b) das Umsetzen des Produktes der Stufe (a) mit alkoholischer HCI und dann Erhitzen des Reaktionsgemisches zur Gewinnung des gewünschten Produktes oder
(c) das Umsetzen des Produktes der Stufe (a) mit Methansulfonsäure und anschließendes Behandeln mit wässerigem Alkohol zur Gewinnung des gewünschten Produktes.
EP80105409A 1979-09-11 1980-09-10 4-(Substituierte Thiazolyl)-3-hydroxy-3-pyrrolin-2,5-dion-Verbindungen, Verfahren zur Herstellung und sie enthaltende pharmazeutische Zusammensetzung Expired EP0025232B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT80105409T ATE2271T1 (de) 1979-09-11 1980-09-10 4-(substituierte thiazolyl)-3-hydroxy-3-pyrrolin2,5-dion-verbindungen, verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzung.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/074,465 US4298743A (en) 1979-09-11 1979-09-11 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
US74465 1979-09-11

Publications (2)

Publication Number Publication Date
EP0025232A1 EP0025232A1 (de) 1981-03-18
EP0025232B1 true EP0025232B1 (de) 1983-01-19

Family

ID=22119703

Family Applications (1)

Application Number Title Priority Date Filing Date
EP80105409A Expired EP0025232B1 (de) 1979-09-11 1980-09-10 4-(Substituierte Thiazolyl)-3-hydroxy-3-pyrrolin-2,5-dion-Verbindungen, Verfahren zur Herstellung und sie enthaltende pharmazeutische Zusammensetzung

Country Status (9)

Country Link
US (1) US4298743A (de)
EP (1) EP0025232B1 (de)
JP (1) JPS5646809A (de)
AT (1) ATE2271T1 (de)
DE (1) DE3061688D1 (de)
DK (1) DK384280A (de)
ES (1) ES8105996A1 (de)
GR (1) GR70200B (de)
PT (1) PT71755B (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379791A (en) * 1979-09-11 1983-04-12 Merck & Co., Inc. 4-(Substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4700901A (en) * 1985-08-19 1987-10-20 Breville R & D Pty. Limited Food processors
WO1992009586A1 (en) * 1990-11-30 1992-06-11 Otsuka Pharmaceutical Co., Ltd. Active oxygen inhibitor
MY128323A (en) * 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
US6313156B1 (en) 1999-12-23 2001-11-06 Icos Corporation Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors
DE10029077A1 (de) * 2000-06-13 2001-12-20 Bayer Ag Thiazolylsubstituierte Heterocyclen
EP1422218B1 (de) * 2001-08-10 2012-03-21 Shionogi & Co., Ltd. Antivirales mittel
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
BRPI0807717A2 (pt) 2007-04-20 2014-05-20 Deciphera Pharmaceuticals Llc Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
MX2011004535A (es) 2008-10-29 2011-11-18 Deciphera Pharmaceuticals Llc Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas.
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
RU2018138195A (ru) 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
DK2931713T3 (en) 2012-12-17 2017-01-30 Parion Sciences Inc CHLORPYRAZINE CARBOXAMIDE DERIVATIVES USED FOR THE TREATMENT OF DISEASES BENEFITED BY INDEPENDENT MOSPHEREWIN
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
CN118416236A (zh) 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
WO2019152719A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE599556A (de) * 1960-02-01
US3340263A (en) * 1964-02-14 1967-09-05 Ciba Geigy Corp Amino-pyrroles
GB1127875A (en) * 1967-03-23 1968-09-18 Parke Davis & Co 4-(5-nitro-2-furyl) thiazolyl hydantoins and hydrouracils
GB1304174A (de) * 1969-03-07 1973-01-24

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7342037B2 (en) 2002-12-31 2008-03-11 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7666895B2 (en) 2002-12-31 2010-02-23 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7737283B2 (en) 2002-12-31 2010-06-15 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments

Also Published As

Publication number Publication date
ES494933A0 (es) 1981-07-01
JPS5646809A (en) 1981-04-28
DK384280A (da) 1981-03-12
ATE2271T1 (de) 1983-02-15
DE3061688D1 (en) 1983-02-24
US4298743A (en) 1981-11-03
GR70200B (de) 1982-08-31
ES8105996A1 (es) 1981-07-01
PT71755B (en) 1982-03-19
PT71755A (en) 1980-09-01
EP0025232A1 (de) 1981-03-18

Similar Documents

Publication Publication Date Title
EP0025232B1 (de) 4-(Substituierte Thiazolyl)-3-hydroxy-3-pyrrolin-2,5-dion-Verbindungen, Verfahren zur Herstellung und sie enthaltende pharmazeutische Zusammensetzung
US4296237A (en) 4-(Pyridyl, piperazinyl and thiazolyl substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
US4342776A (en) 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4256758A (en) 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4432992A (en) 4-[5(and 4)-Substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4528291A (en) 2-(4'-Pyridinyl)-thiazole compounds and their use in increasing cardiac contractility
US4107310A (en) Quinoline-3-carboxamides
US4554276A (en) 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US4166851A (en) Certain imidazo(1,2a)pyridine derivatives
US4379791A (en) 4-(Substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4377588A (en) 4-(Substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4537902A (en) 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4387101A (en) Thiazolidine derivatives and their use
US4431660A (en) (4'-Biphenylyloxy and-thio-oxy)-3-hydroxy-3-pyrroline-2,5-diones and a method of treating calcium oxalate renal lithiasis therewith
US4408047A (en) Imidazodiazines
US4428959A (en) 4-Alkylsubstituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4431652A (en) 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
US5116855A (en) Rhodanine derivatives and pharmaceutical compositions
US4337258A (en) 2,4-Dioxo-4-substituted-1-butanoic acid derivatives useful in treating urinary tract calcium oxalate lithiasis
CA2163950A1 (en) 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
US4448786A (en) 4-Naphthyl and substituted naphthyl-3-hydroxy-3-pyrroline-2,5-diones and their use as inhibitors of glycolic acid oxidase
US4349561A (en) 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
IL44311A (en) Alpha-(5-oxo-10,11-dihydrodibenzo (a,d) cyclohepten-2-yl)-alkanoic acid derivatives processes for their preparation and pharmaceutical compositions containing them
US4423063A (en) 2,4-Dioxo-4-substituted-1-butaoic acid derivatives useful in treating urinary track calcium oxalate lithiasis
EP0348257A2 (de) (Hetero)Aryl-diazol-Derivate, Verfahren zu deren Herstellung und deren Verwendung in der Therapie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LU NL SE

ITCL It: translation for ep claims filed

Representative=s name: SOCIETA' ITALIANA BREVETTI S.P.A.

17P Request for examination filed

Effective date: 19810318

ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 2271

Country of ref document: AT

Date of ref document: 19830215

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3061688

Country of ref document: DE

Date of ref document: 19830224

ET Fr: translation filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19830907

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19830930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19840430

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19840601

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19840630

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19840830

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19840930

Year of fee payment: 5

Ref country code: NL

Payment date: 19840930

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19850704

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19860401

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19860910

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19860911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19860930

Ref country code: CH

Effective date: 19860930

Ref country code: BE

Effective date: 19860930

BERE Be: lapsed

Owner name: MERCK & CO. INC.

Effective date: 19860930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19870527

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19870602

GBPC Gb: european patent ceased through non-payment of renewal fee
REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19881118

EUG Se: european patent has lapsed

Ref document number: 80105409.9

Effective date: 19870812

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT